BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Valori CF, Possenti A, Brambilla L, Rossi D. Challenges and Opportunities of Targeting Astrocytes to Halt Neurodegenerative Disorders. Cells 2021;10:2019. [PMID: 34440788 DOI: 10.3390/cells10082019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Yi S, Wang L, Wang H, Ho MS, Zhang S. Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective. IJMS 2022;23:14753. [DOI: 10.3390/ijms232314753] [Reference Citation Analysis]
2 D’souza A, Nozohouri S, Bleier BS, Amiji MM. CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood–Brain Barrier and Towards Specific Cellular Targeting. Pharm Res 2022. [DOI: 10.1007/s11095-022-03433-5] [Reference Citation Analysis]
3 Wu C, Yang L, Feng S, Zhu L, Yang L, Liu TC, Duan R. Therapeutic non-invasive brain treatments in Alzheimer's disease: recent advances and challenges. Inflamm Regen 2022;42:31. [PMID: 36184623 DOI: 10.1186/s41232-022-00216-8] [Reference Citation Analysis]
4 Yang W, Yue H, Lu G, Wang W, Deng Y, Ma G, Wei W. Advances in Delivering Oxidative Modulators for Disease Therapy. Research 2022;2022:1-24. [DOI: 10.34133/2022/9897464] [Reference Citation Analysis]
5 Eraso-Pichot A, Pouvreau S, Olivera-Pinto A, Gomez-Sotres P, Skupio U, Marsicano G. Endocannabinoid signaling in astrocytes. Glia 2022. [PMID: 35822691 DOI: 10.1002/glia.24246] [Reference Citation Analysis]
6 Needham H, Torpey G, Flores CC, Davis CJ, Vanderheyden WM, Gerstner JR. A Dichotomous Role for FABP7 in Sleep and Alzheimer’s Disease Pathogenesis: A Hypothesis. Front Neurosci 2022;16:798994. [DOI: 10.3389/fnins.2022.798994] [Reference Citation Analysis]
7 D'Ambrosi N, Cozzolino M, Apolloni S. The Contribution of Non-Neuronal Cells in Neurodegeneration: From Molecular Pathogenesis to Therapeutic Challenges. Cells 2022;11:193. [PMID: 35053309 DOI: 10.3390/cells11020193] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Camponeschi C, De Carluccio M, Amadio S, Clementi ME, Sampaolese B, Volonté C, Tredicine M, Romano Spica V, Di Liddo R, Ria F, Michetti F, Di Sante G. S100B Protein as a Therapeutic Target in Multiple Sclerosis: The S100B Inhibitor Arundic Acid Protects from Chronic Experimental Autoimmune Encephalomyelitis. IJMS 2021;22:13558. [DOI: 10.3390/ijms222413558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]